Abstract 198P
Background
Geographic access to medical care varies for nearly every specialty in India. Brachytherapy (BT) is emblematic of several of these access difficulties since it necessitates specialized equipment, the capacity to maintain a radioactive source, and particular skill sets. To quantify the unmet infrastructure needs, we conducted this study to report the availability of brachytherapy treatment units in relation to state-level population, and gynaecologic cancer incidence in India.
Methods
The availability of BT resources at the state level in India was obtained from the IAEA database. The population of each state was estimated using data from the Government of India's census. Using National Cancer Registry program data, the number of cancer cases was approximated for each state and union territory. The total number of gynaecological cancers that required BT was determined. BT capacity was estimated at three procedures per unit per day for 240 days(Excluding holidays and weekends) as follows: number of BT units x 240 x 3. The disparity between available and needed infrastructure was used to compute the deficit in BT units. Number of BT facilities available in medical colleges across India were calculated. The BT infrastructure was also compared to those of other nations in terms of the number of BT units available per million people and for various malignancies.
Results
India has 1 brachytherapy unit every 42,93,031 population. With respect to state wise data, 21 states and union territories had deficits of brachytherapy units. The maximum deficit was seen in Uttar Pradesh. The maximum units per 10,000 cancer patients was noted in Delhi (7) and the least was noted in the North Eastern states (<1). In brachytherapy of gynaecological cancers a deficit ranging from 1-75 units were noted across the states. It was noted that only 104 out of the 613 medical colleges in India had BT facilities. India had 1 BT machine for every 4181 cancer patients when compared to USA ( 2956 patients), Germany (2754 patients) and Japan (4303 patients).
Conclusions
The study identified the deficits of BT facilities in India and provides a direction for the development of BT infrastructure.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Abhishek Krishna.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
140P - Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience
Presenter: CHINNU JOMI
Session: Poster viewing 03
141P - Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
Presenter: Yu-Chieh Tsai
Session: Poster viewing 03
143P - Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma
Presenter: Shun Iwasa
Session: Poster viewing 03
144P - Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Presenter: Takanori Hayase
Session: Poster viewing 03
145P - Treatment outcomes and FGFR alterations in unresectable locally advanced or metastatic urothelial cancer in Taiwan
Presenter: Jian-Ri Li
Session: Poster viewing 03
146P - Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: A propensity score-matched Chinese cohort
Presenter: WAICHAN LOK
Session: Poster viewing 03
Resources:
Abstract
147P - Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) “platinum-ineligible” patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice
Presenter: Javier Molina Cerrillo
Session: Poster viewing 03
149P - A need for clear definitions and improved management for BCG-unresponsive tumors in Asia-Pacific
Presenter: Lui Shiong Lee
Session: Poster viewing 03
Resources:
Abstract